首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial

【2h】

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial

机译：修改后的痘苗安卡拉-巴伐利亚北欧天花疫苗在未接种痘苗和有经验的人类免疫缺陷病毒感染者中的安全性和免疫原性：一项开放标签受控的临床II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Open Forum Infectious Diseases
作者

展开▼
作者单位

展开▼
年(卷),期 2016(3),1
年度 2016
页码 ofv183
总页数 1
原文格式 PDF
正文语种
中图分类病毒传染病;
关键词

相似文献

外文文献
中文文献

1. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial [J] . Open Forum Infectious Diseases . 2016,第1期

机译：修改后的痘苗安卡拉-巴伐利亚北欧天花疫苗在未接种过痘苗和有经验的人类免疫缺陷病毒感染者中的安全性和免疫原性：一项开放标签，受控的临床II期试验
2. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial [J] . Alfred von Krempelhuber, David Barker, Edgar Turner Overton, Open Forum Infectious Diseases . 2015,第2期

机译：修改后的痘苗安卡拉-巴伐利亚北欧天花疫苗在未接种过痘苗和有经验的人类免疫缺陷病毒感染者中的安全性和免疫原性：一项开放标签，受控的临床II期试验
3. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. [J] . Siberry GK, Williams PL, Lujan Zilbermann J, The Pediatric infectious disease journal . 2010,第5期

机译：在人免疫缺陷病毒感染的青少年中，脑膜炎球菌（A，C，Y和W-135组）多糖白喉类毒素结合疫苗的安全性和免疫原性的I / II期开放性试验。
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial [O] . Edgar Turner Overton, Jack Stapleton, Ian Frank, 2015

机译：修改后的痘苗安卡拉-巴伐利亚北欧天花疫苗在未接种痘苗和有经验的人类免疫缺陷病毒感染者中的安全性和免疫原性：一项开放标签受控的临床II期试验
6. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects. [O] . Richard N Greenberg, Christine M Hay, Jack T Stapleton, 2016

机译：随机，双盲，安慰剂对照II期试验研究改良痘痘安卡拉天花疫苗（mVa-BN®）在56-80岁受试者中的安全性和免疫原性。

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial

著录项

相似文献

相关主题

期刊订阅